Suche
Filter by content type
Filter by content year
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
März 24, 2026 - … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house …
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
März 10, 2026 - … of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting … of the adjusted results to BioNTech’s measures based on IFRS Accounting Standards and more information can … transactions to the extent disclosed. The guidance is based on non-IFRS measures and excludes certain effects …
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
März 10, 2026 - … attention to a new venture, dedicated to enabling mRNA-based technologies to reach their full potential,” said … and advancing the research and development of mRNA-based innovations with disruptive potential. To this end, … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house …
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
Februar 24, 2026 - … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house …
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
Januar 28, 2026 - … and strengthening an inclusive culture. She will be based in the Company’s headquarters in Mainz, Germany. Kylie … business needs. This includes the shift from a country-based structure to a centralized model for more than 40 … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house …
BioNTech und OncoC4 erhalten Orphan-Drug-Status der FDA für Gotistobart bei Patientinnen und Patienten mit Plattenepithelkarzinom der Lunge
Januar 12, 2026 - … incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 24(11):1206-1218. 2 Lau S. et al. … Analysis of 922,217 Lung Cancer Patients from the US Based on the Most Recent Data from the SEER Database (April … incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 24(11):1206-1218. 2 Lau S. et al. …
BioNTech and OncoC4 Receive FDA Orphan Drug Designation for Gotistobart in Squamous Non-Small Cell Lung Cancer
Januar 12, 2026 - … had progressed following anti-PD-(L)1 therapy and platinum-based chemotherapy. These data were previously announced and … who have progressed on PD-(L)1 inhibitors and platinum-based chemotherapy. The non-pivotal stage of the trial … chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house …
BioNTech Receives FDA Fast Track Designation for mRNA Cancer Immunotherapy Candidate BNT113 in HPV16+ Head and Neck Cancer
Januar 21, 2026 - … an unmet medical need. The designation has been granted based on preliminary safety and efficacy data from the … (CAR) T cell therapies, and mRNA cancer immunotherapies. Based on its deep expertise in mRNA development and in-house … The forward-looking statements in this statement are based on BioNTech’s current expectations and beliefs of …
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
Januar 12, 2026 - … geographies. BioNTech does not currently anticipate the recognition of revenues from the sale of any oncology … (CAR) T cell therapies, and mRNA cancer immunotherapies. Based on its deep expertise in mRNA development and in-house … The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of …
